Orion Pharma Limited announcements
187 Dhaka Stock Exchange announcements for Orion Pharma Limited (ORIONPHARM) since 2013: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2022 (24).
- Resumption after record date
Trading of the shares of the Company will resume on 05.12.2022 after record date.
- Suspension for Record date
Trading of the shares of the Company will remain suspended on record date i.e., 04.12.2022 for EGM and AGM.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 30.11.2022 to 01.12.2022. Trading of the shares will remain suspended on record date i.e., 04.12.2022 for EGM and AGM.
- (Q1 Un-audited): Consolidated EPS was Tk. 0.72 for July-September 2022 as against Tk. 0.30 for July-September 2021; Cons
(Q1 Un-audited): Consolidated EPS was Tk. 0.72 for July-September 2022 as against Tk. 0.30 for July-September 2021; Consolidated NOCFPS was Tk. 2.25 for July-September 2022 as against Tk. 1.52 for July-September 2021. Consolidated NAV per share (including revaluation surplus) was Tk. 92.65 as on September 30, 2022 and Tk. 82.53 as on June 30, 2022. Consolidated NAV per share (excluding revaluation surplus) was Tk. 84.75 as on September 30, 2022 and Tk. 74.62 as on June 30, 2022. (cont.)
- Q1 Financials
(Continuation news of ORIONPHARM): Reasons for deviation in EPS: EPS has been increased as two of the company 's subsidiaries (Orion Power Meghnaghat Limited and Dutch Bangla Power & Associates Limited) are fully operational now. (end)
The first part of this announcement is missing from the archive. - The Board of Directors has recommended 10\% cash dividend for the year ended June 30, 2022. The Board has also considere
The Board of Directors has recommended 10\% cash dividend for the year ended June 30, 2022. The Board has also considered and recommended the proposal for approval of the shareholders regarding Related Party Transaction for the Financial year ended June 30, 2022 and in this regard, the Board also advised to hold an EGM. Date of AGM and EGM: 28.12.2022, Time of AGM and EGM: 3:00 PM and 3:45 PM respectively, Venue: Digital Platform. Record Date for AGM and EGM: 04.12.2022. (cont.1)
- (Continuation news of ORIONPHARM): The Company has reported Consolidated EPS of Tk. 3.62, Consolidated NAV per share (In
(Continuation news of ORIONPHARM): The Company has reported Consolidated EPS of Tk. 3.62, Consolidated NAV per share (Including Revaluation Surplus) of Tk. 82.53, Consolidated NAV per share (Excluding Revaluation Surplus) of Tk. 74.62 and Consolidated NOCFPS of Tk. 4.96 for the year ended June 30, 2022 as against Tk. 4.01, Tk. 79.76, Tk. 71.79 and Tk. 11.07 respectively for the same period of the previous year. (cont.2)
The first part of this announcement is missing from the archive. - Price Limit Open
There will be no price limit on the trading of the shares of the Company today (14.11.2022) following its corporate declaration. However, as per the BSEC Order No. BSEC/CMRRCD/2001-07/39 dated July 28, 2022, the floor price shall be applicable accordingly.
- Dividend Declaration and EGM for Related Party Transaction
(Continuation news of ORIONPHARM): Reasons for significant changes in NOCFPS: i) Decrease in cash collection from customers and others. ii) Increase in payment to suppliers and others. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2022.
- Board Meeting schedule under LR 19(1)
The Company has further informed that, the Board meeting under LR 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on November 13, 2022 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2022.
- Query Response
In response to a DSE query dated September 07, 2022, the Company has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike and increase in volume of shares.
- Refer to their earlier news disseminated by DSE on 26.04.2022 regarding Verbal consent from BPDB to purchase electricity
Refer to their earlier news disseminated by DSE on 26.04.2022 regarding Verbal consent from BPDB to purchase electricity, the Company has further informed that Government has approved the extension of existing contracts of 100 MW each HFO based rental power plants namely Orion Power Meghnaghat Limited and Dutch Bangla Power & Associates Limited (Subsidiary Companies of Orion Pharma Limited) to purchase of electricity on \"No Electricity No Payment\" basis for 2 Years. (cont.)
- Government approval for purchase of electricity
(Continuation news of ORIONPHARM): Subsequently, both the companies signed the amended Power Purchase Agreement (PPA) with BPDB on April 28, 2022 to be effective from March 24, 2022. Orion Pharma Ltd. being the Parent Company, the resuming of both the power plants will have a substantial positive impact on its profitability including EPS, NAV and NOCFPS. (end)
The first part of this announcement is missing from the archive. - (Q3 Un-audited): Consolidated EPS was Tk. 1.05 for January-March 2022 as against Tk. 0.95 for January-March 2021; Consol
(Q3 Un-audited): Consolidated EPS was Tk. 1.05 for January-March 2022 as against Tk. 0.95 for January-March 2021; Consolidated EPS was Tk. 3.07 for July 2021-March 2022 as against Tk. 2.98 for July 2020-March 2021. Consolidated NOCFPS was Tk. 3.44 for July 2021-March 2022 as against Tk. 7.52 for July 2020-March 2021. (cont.)
- Q3 Financials
(Continuation news of ORIONPHARM): Consolidated NAV per share (excluding Revaluation Surplus) was Tk. 74.03 as on March 31, 2022 and Tk. 71.79 as on June 31, 2021. NAV per share (including Revaluation Surplus) was Tk. 81.96 as on March 31, 2022 and Tk. 79.76 as on June 31, 2021. (end)
The first part of this announcement is missing from the archive. - The Company has informed that Bangladesh Power Development Board (BPDB) has verbally informed about the approval given b
The Company has informed that Bangladesh Power Development Board (BPDB) has verbally informed about the approval given by the Cabinet Committee on Public Purchase (CCPP) of the Government of Bangladesh to purchase electricity on a \" No Electricity, No payment\" basis for 2 years. In addition, both the power plants have been verbally instructed by BPDB to resume operation. Accordingly, both the subsidiaries have already started operation and are supplying electricity to the (cont.)
- Verbal consent from BPDB to purchase electricity
Continuation news of ORIONPHARM): national grid. OPL being the Parent Company, the resuming of both the power plants following the renewal of contracts with BPDB will have a substantial positive impact on its profitability including EPS, NAV and NOCFPS from fourth quarter (Q4). Both the power plants are waiting for the official letters from BPDB and are in the process of finalizing amended PPA with BPDB for the new term of 2 years. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 26, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2022.
- (Q2 Un-audited): Consolidated EPS was Tk. 1.72 for October-December 2021 as against Tk. 1.21 for October-December 2020;
(Q2 Un-audited): Consolidated EPS was Tk. 1.72 for October-December 2021 as against Tk. 1.21 for October-December 2020; Consolidated EPS was Tk. 2.02 for July-December 2021 as against Tk. 2.03 for July-December 2020. Consolidated NOCFPS was Tk. 1.87 for July-December 2021 as against Tk. 2.34 for July-December 2020. (Cont.)
- Q2 Financials
(Continuation news of ORIONPHARM): Consolidated NAV per share including revaluation surplus was Tk. 80.94 as on December 31, 2021 and Tk. 79.76 as on June 30, 2021. Consolidated NAV per share excluding revaluation surplus was Tk. 72.99 as on December 31, 2021 and Tk. 71.79 as on June 30, 2021. (end).
The first part of this announcement is missing from the archive. - Dividend Disbursement
The Company has informed that it has disbursed the cash dividend for the year ended June 30, 2021 to the respective shareholders.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2021.
- Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Entity rating (Surveillance) of the Company as \"A1\
Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Entity rating (Surveillance) of the Company as \"A1\" along with a stable outlook based on audited financial statements as of June 30, 2021, bank liability position as of November 30, 2021 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.